Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell
Phase of Trial: Phase I/II
Latest Information Update: 21 Feb 2019
Price : $35 *
At a glance
- Drugs Romiplostim (Primary)
- Indications Thrombocytopenia
- Focus Adverse reactions; Therapeutic Use
- Acronyms AGRAH003
- 13 Feb 2019 Status changed from active, no longer recruiting to completed.
- 13 Jun 2017 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology